(Assayed daily, Monday to Friday)
Everolimus is marketed as Certican for transplant immunosuppression, and Afinitor as an anti-tumour agent. Everolimus is structurally very similar to sirolimus, and has a similar mechanism of action. Monitoring of whole blood everolimus concentrations is recommended when used for prevention of rejection following allograft.
|Turnaround:||>95% of samples are turned round within 24 h of receipt on weekdays. We aim to issue results by 5 pm on samples received by 1.30 pm and by the following workday morning for samples received up to 3.30 pm|
|Sample:||2 mL EDTA-anticoagulated whole blood just pre-dose (12 h post-dose for twice daily dosing)|
|Method:||Liquid chromatography-tandem mass spectrometry|
|Principle:||Everolimus is measured in whole blood using a validated in-house liquid chromatography-tandem mass spectrometry (LC-MS/MS) method. The IDM laboratory participates in the International Proficiency Testing Scheme for everolimus.|
Immunosuppressive drugs require monitoring because they act within a narrow range of concentrations and show large inter-individual differences in drug handling and efficacy which make standard dosing regimens impractical. Therapy aims to suppress the immune system sufficiently to prevent graft rejection or autoimmune disease but without either acute toxicity (e.g. renal or gastrointestinal damage) or the increased generic risks of infection or malignancy. IDM provides the most valuable method for regulating dosage in these circumstances and because no real time measurement of “immunosuppression” exists. The principle is to adjust dosage on the basis of standardised drug level measurements that can be targeted to a therapeutic range appropriate for the individual patient. Such adjustments must be made in conjunction with clinical information and other laboratory test results. IDM therapeutic ranges may vary with:
The customary single blood sample used for monitoring is the trough drug level, determined just prior to dosage and at a constant interval from the time of the previous dose. Measurements at alternative times, e.g. 2 hours post dose (C2), may be useful in certain situations. For ciclosporin in particular, a C2 level might offer an improved estimate of total early drug exposure. However, it may be difficult to obtain accurately if dosage and phlebotomy times vary. Therapeutic ranges are higher for C2 than for trough drug levels because drug concentrations peak at around 2 h post dose. Contact the IDM Laboratory for more information if required.
Immunosuppressive drug concentrations may also be profoundly affected by:
In addition to use as an immunosuppressant, everolimus is being used as an antitumour drug and has been licensed for use in treating advanced renal cell carcinoma with the alternate trade name of Afinitor. Currently there is no information available on a suitable therapeutic range for these effects.
The frequency at which IDM is performed generally decreases with time after transplant. It is rarely necessary to monitor levels more than three times weekly e.g. Monday, Wednesday and Friday, because the half-lives of the immunosuppressants exceed 12 h. Consequently, drug levels will not re-equilibrate for 2–3 days after changes in dosage. However, immediately after transplantation, daily monitoring may be required in unstable (especially paediatric) patients but the frequency may decrease to once three or six monthly in long-term stable patients. The frequency of testing should be determined by any changes in likely modulators of drug levels, that is:
The examination of drug profiles during a dosage interval may be a valuable adjunct to conventional trough level monitoring. The additional information available from these pharmacokinetic studies may reveal unexpected abnormalities in the rate and extent of drug absorption and disposition.
|Turnaround: within 24hrs.|
|Price: Contact Lab|
|IDM service: kch-tr.KCHIDMService@nhs.net|
|Therapeutic Ranges: (males = females)|
Results may vary with concomitant immunosuppressive therapy and time after and indication for transplantation. Results of < 2 µg/L and > 12 µg/L (ng/mL) may be associated with an increased risk of rejection or side-effects, respectively, and are not recommended.
Currently a therapeutic range of 3 – 8 µg/L is suggested (Oellerich and Armstrong, Therapeutic Drug Monitoring 2006; 28: 720–725) for everolimus when combined with a calcineurin inhibitor (CNI) for immunosuppression following allograft.
A therapeutic range for anti-tumour action is currently not defined, but is likely to be significantly higher than that required for immunosuppression.